Period:
Draw Mode:
| Volume | 43,464 |
|
|||||
| News | - | ||||||
| Day High | 5.09 | Low High |
|||||
| Day Low | 4.66 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Marker Therapeutics Inc | MRKR | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.08 | -1.62% | 4.85 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 4.80 | 4.66 | 5.09 | 4.81 | 4.93 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 441 | 43,464 | $ 4.77 | $ 207,290 | - | 0.6706 - 9.6799 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:55:34 | 10 | $ 4.85 | USD |
Marker Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 42.72M | 8.81M | - | 9.01M | -29.93M | -3.40 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Marker Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MRKR Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 5.29 | 5.55 | 4.66 | 5.12 | 23,050 | -0.44 | -8.32% |
| 1 Month | 5.58 | 6.7999 | 4.66 | 5.70 | 63,180 | -0.73 | -13.08% |
| 3 Months | 3.06 | 9.6799 | 3.06 | 6.19 | 136,928 | 1.79 | 58.5% |
| 6 Months | 0.8285 | 9.6799 | 0.6706 | 2.38 | 507,399 | 4.02 | 485.4% |
| 1 Year | 3.34 | 9.6799 | 0.6706 | 2.69 | 366,313 | 1.51 | 45.21% |
| 3 Years | 15.30 | 37.70 | 0.6706 | 15.30 | 885,788 | -10.45 | -68.3% |
| 5 Years | 100.10 | 102.50 | 0.6706 | 21.45 | 680,933 | -95.25 | -95.15% |
Marker Therapeutics Description
| Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart. |